Fisher Asset Management LLC Trims Stock Position in G1 Therapeutics, Inc. (NASDAQ:GTHX)

Posted by on Apr 25th, 2023

Fisher Asset Management LLC cut its stake in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) by 4.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,809,444 shares of the company’s stock after selling 125,888 shares during the quarter. Fisher Asset Management LLC owned 6.55% of G1 Therapeutics worth $15,255,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of GTHX. Swiss National Bank lifted its position in G1 Therapeutics by 9.1% during the first quarter. Swiss National Bank now owns 70,400 shares of the company’s stock valued at $535,000 after purchasing an additional 5,900 shares during the last quarter. Raymond James & Associates lifted its position in G1 Therapeutics by 72.0% during the first quarter. Raymond James & Associates now owns 397,879 shares of the company’s stock valued at $3,024,000 after purchasing an additional 166,564 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in G1 Therapeutics by 6.7% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 53,625 shares of the company’s stock valued at $408,000 after purchasing an additional 3,383 shares during the last quarter. MetLife Investment Management LLC lifted its position in G1 Therapeutics by 56.5% during the first quarter. MetLife Investment Management LLC now owns 23,409 shares of the company’s stock valued at $178,000 after purchasing an additional 8,450 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in G1 Therapeutics by 7.9% during the first quarter. Dimensional Fund Advisors LP now owns 566,011 shares of the company’s stock valued at $4,302,000 after purchasing an additional 41,278 shares during the last quarter. 53.13% of the stock is currently owned by institutional investors.

G1 Therapeutics Price Performance

NASDAQ:GTHX opened at $2.66 on Tuesday. The company has a fifty day moving average of $3.10 and a 200 day moving average of $6.02. G1 Therapeutics, Inc. has a 52 week low of $2.41 and a 52 week high of $17.49. The company has a current ratio of 5.04, a quick ratio of 4.59 and a debt-to-equity ratio of 1.12.

G1 Therapeutics (NASDAQ:GTHX – Get Rating) last posted its quarterly earnings results on Wednesday, March 1st. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.12. G1 Therapeutics had a negative net margin of 287.63% and a negative return on equity of 209.92%. The company had revenue of $10.25 million during the quarter, compared to analyst estimates of $9.61 million. On average, equities research analysts predict that G1 Therapeutics, Inc. will post -1.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. upgraded shares of G1 Therapeutics from an “underweight” rating to a “neutral” rating and lifted their target price for the company from $7.00 to $10.00 in a research report on Monday, January 30th. Citigroup began coverage on shares of G1 Therapeutics in a report on Wednesday, January 4th. They issued a “buy” rating for the company. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of G1 Therapeutics in a report on Thursday, March 2nd. EF Hutton Acquisition Co. I lowered their price objective on shares of G1 Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a report on Monday, February 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $18.00 price objective on shares of G1 Therapeutics in a report on Wednesday, April 19th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.60.

G1 Therapeutics Company Profile

(Get Rating)

G1 Therapeutics, Inc engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Recommended Stories

Want to see what other hedge funds are holding GTHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating).

Institutional Ownership by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.